Bryan Walser, M.D., J.D.
Dr. Walser served as the Chief Executive Officer at Allergen Research Corporation. Dr. Walser served as an Interim Chief Executive Officer of Perlegen Sciences, Inc. since May 1, 2007. He had overall responsibility for management of Perlegen Sciences, Inc.'s operations, organizational development and honing Perlegen's strategic mission. Dr. Walser served as the Vice President, Corporate Strategy and Corporate Affairs for Chiron Corporation in Emeryville, California since November 2001. Before that, he was a principal with WRW Advisors in Los Angeles, California, and an emergency room physician at UCLA. Prior to joining Chiron, Dr. Walser was an independent management consultant, working with The Rockefeller Foundation and the Boston Consulting Group. Dr. Walser also spent five years with The Boston Consulting Group's healthcare practice, based in Los Angeles. He serves as a Director of GeneFluidics, Inc. He served as a Director of Perlegen Sciences, Inc. He has published a number of peer-reviewed articles on topics ranging from renal physiology and tropical medicine to international regulatory policy. He is an International Health Policy Fellow in Basel, Switzerland of F.Hoffmann-La Roche AG. Dr. Walser trained in the Emergency Medicine program at UCLA. He holds a BS in Biology and an Undergraduate Degree from Stanford University. Dr. Walser earned his Medical Degree from the University of Virginia School of Medicine and his Law Degree, magna cum laude, from Harvard Law School.
Mr. Michael Williams has served as Non-Executive Director of Phylogica Ltd. Since January 3, 2018. Mr. Williams served as Chief Operating Officer of Intarcia Therapeutics, Inc. from May 4, 2015 to November 2016. Prior to joining Intarcia, Mr. Williams served as Head of Global Marketing Division Tokyo at Takeda Pharmaceutical Company Limited since July 01, 2013 and served as its Head of Global Marketing for Takeda Pharmaceuticals International GmbH. He was responsible for establishing Takeda's first Global Marketing organization that included Global Market Access, Customer Insights and Global Brand Management. Mr. Williams worked at Pfizer from 2006 to 2012, prior to joining Takeda. His most recent position at Pfizer was Vice President, Global Commercial Development, Strategy and Innovation Primary Care, where he was instrumental in transforming commercial input into clinical development programs in the Primary Care Business Unit, as well as improving the performance of in-line brands such as Lyrica, Spiriva and Chantix. Before Pfizer, Mr. Williams held various roles of escalating responsibility at Bristol-Myers Squibb from 1993 to 2006. These included positions at BMS' EMEA Headquarters in Paris as the Vice President for European Marketing & Operations, in Malaysia and in the United States. Earlier in his career Mr. Williams held positions at British Telecom and Texas Instruments. He holds a Bachelor of Arts degree in Education, and a Postgraduate Certificate in Education from University College North Wales. He completed postgraduate research in psychology at the University of Reading.
Sadik Esener, Ph.D.
Dr. Esener is the director of the Center for Early Detection Research and Wendt Family Endowed Chair in Early Cancer Detection at the Biomedical Engineering Department at OHSU. Prior to joining OHSU, Esener served in several leadership roles at the University of California, San Diego, in which he achieved results by bringing together scientists and technology across disciplines. He served as the director and principal investigator of the NanoTumor Cancer, a Nanotechnology Center of Excellence funded by the National Cancer Institute. He has also held leadership roles with the Center for Heterogeneously Integrated Photonics Systems (CHIPS) as well as the Opto-Electronic Stacked Processors (OESP) and the Fast Read-out Optical Data Storage Industrial Consortium, which were both funded by DARPA. Dr. Esener has had many experiences translating technologies developed at the university. He has founded more than 10 companies in the biotech and optics space including Nanogen, Optical Micro-Machines, Parallel Solutions, Genoptix, Call/Recall, Ziva, and Sonrgy. Esener received his Ph.D. in applied physics and electrical engineering from the University of California, San Diego. He has published more than 375 journal and conferences articles, and made more than 250 presentations in international scientific meetings, 60 of which were invited. He holds 23 issued patents, has authored several book chapters, and organized and chaired scientific international conferences. Esener co-founded and served on the board of directors and scientific advisory boards of several companies.
Jean-Frédéric Saunière, M.D., Ph.D.
Dr. Saunière is currently medical oncologist at Institut Paoli-Calmettes (IPC) in Marseille, France where he coordinates translational research and early clinical research activities of the Institute. His role also involves patent filing and partnerships with academics and pharmaceutical companies. His expertise is in medical oncology and pharmacology. He is also the Director of IPC Drug Discovery Group aiming at discovering new drugs to treat cancers. Dr. Saunière brings 25 years of experience in drug development and business development. He has led early phase I and phase II studies in the area of oncology and metabolic diseases at Pfizer US. Dr. Saunière also served as Director of Corporate Licensing & Business Development at Pfizer, New York and as VP of Anaderm, a subsidiary of Pfizer. He was also a senior executive in several early stage pharmaceutical companies in the US and CEO of Shogoo Pharmaceutical in Basel, Switzerland. He is also the holder of several patents for drugs in oncology and metabolic disorders. In the last five years, Dr. Saunière served as chairman of the board of directors of Deviris Pharma in Basel, Board member at Balonco in Basel, Switzerland, Shogoo Pharmaceuticals and currently COO at Mediapharma, a discovery and development company in immuno-oncology in Rome, Italy.
John Foley, M.D.
Dr. Foley is Director of Rocky Mountain Multiple Sclerosis (MS) Clinic and Rocky Mountain MS Research Group, LLC, in Salt Lake City, UT. He also serves as President Emeritus and Chief of the Division of Neurology at LDS Hospital, Salt Lake City. He received his MD from the Medical College of Wisconsin, Milwaukee, and completed his Internship and Residency from University of Utah Medical Center, Salt Lake City. His clinical practice focuses on the intersection between optimizing patient care and new drug development to further combat progressive disabilities associated with MS. Dr Foley has presented numerous papers on MS as well as authored articles in journals such as Annals of Neurology, International Journal of MS Care, and American Journal of Managed Care. He is the past President of the Medical Staff at LDS Hospital and is active member of the American Academy of Neurology, American Association of Electrodiagnostic Medicine, and Consortium of MS Centers.
Mark Backer, Ph.D.
Dr. Backer has technical management experience in the development and manufacturing of a wide variety of biopharmaceuticals including antibodies, proteins, viral-based vaccines and cell therapies. He also has business experience as a biotech startup CEO, and was founding chairman of the contract manufacturing firm Molecular Medicine BioServices (now a division of SAFC Pharma, a Merck KGA company). Dr. Backer’s industry experience began in 1978, when he was the seventh employee of Genentech and initiated its pilot manufacturing operations. He led pioneering efforts in large-scale cell culture technology and ex-vivo expansion and transfection of stem cells. He was most recently Sr. VP, Technical Operations with Jennerex with responsibility for all CMC operations. He also served as CEO of Vaxart (viral-based oral vaccine platform), VP Technical Development with Protein Design Labs, and previously served in positions of increasing responsibility with firms including Aviron (now MedImmune Vaccines), Systemix, IDEC, and Eli Lilly. Dr. Backer received a PhD in Chem. Engineering from the University of Washington, and a BS in Chemistry from Stanford University.
As the third most accurate placekicker in NFL history at the time of his retirement, Rolf Benirschke had an illustrious 10-year career with the San Diego Chargers. Rolf received numerous honors during his career including NFL Man of the Year; Comeback Player of the Year; Philadelphia Sports Writers Association Most Courageous Athlete; NFL Players Association Hero of the Year; NFL Justice Byron Whizzer White Award; and was selected to play in the Pro Bowl. In his second season with the Chargers, Rolf was stricken with a life-threatening disease that led him to create a nationwide patient advocacy and support program for those facing ostomy surgery and IBD. He is the national spokesman for The Crohn’s & Colitis Foundation of America (CCFA), and The Rolf Benirschke Award was created in 2015 to honor community members who have made a significant impact locally for philanthropy, giving back, and leaving a lasting legacy. He was also granted the CCFA national award, The Modell Award for Business Leadership for exemplary volunteer leadership. He has helped raise almost $1 million in an effort to help find the cure for Inflammatory Bowel Disease. In 2004, he became a spokesperson for the 4 million Americans infected with the virus speaking for the National Center for Disease Control, the American Liver Foundation, and many other organizations to raise the awareness of this silent killer. In addition, he started a national awareness and patient support program called, Kick Hep C.
With over 30 years of diverse entrepreneurial endeavors, Mr. Senturia brings a unique perspective to business challenges. His wide range of experience includes starting and leading three software companies, an alternative energy company and a materials science venture, developing more than two million square feet of real estate, and screenwriting in Hollywood. Mr. Senturia joined the Board of Directors of Abreos Biosciences in May, 2014 as Executive Chairman and is working closely with the management team to identify market opportunities, connect with partners, and raise funds.